Target Price | $334.05 |
Price | $348.30 |
Deviation | 4.09% |
Number of Estimates | 27 |
27 Analysts have issued a price target UnitedHealth 2026 . The average UnitedHealth target price is $334.05. This is 4.09% lower than the current stock price. The highest price target is $710.85 104.09% , the lowest is $199.98 42.58% . | |
A rating was issued by 32 analysts: 22 Analysts recommend UnitedHealth to buy, 7 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the UnitedHealth stock has an average upside potential 2026 of 4.09% . Most analysts recommend the UnitedHealth stock at Purchase. |
28 Analysts have issued a sales forecast UnitedHealth 2025 . The average UnitedHealth sales estimate is $452b . This is 7.01% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $474b 12.04% , the lowest is $433b 2.43% .
This results in the following potential growth metrics:
2024 | $400b | 7.71% |
---|---|---|
2025 | $452b | 13.03% |
2026 | $470b | 3.96% |
2027 | $495b | 5.15% |
2028 | $512b | 3.61% |
2029 | $551b | 7.51% |
2030 | $596b | 8.22% |
2031 | $629b | 5.57% |
2032 | $664b | 5.54% |
23 Analysts have issued an UnitedHealth EBITDA forecast 2025. The average UnitedHealth EBITDA estimate is $27.3b . This is 21.92% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $39.5b 12.87% , the lowest is $25.2b 28.01% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $36.4b | 0.15% |
---|---|---|
2025 | $27.3b | 24.94% |
2026 | $29.4b | 7.58% |
2027 | $32.7b | 11.20% |
2028 | $38.0b | 16.43% |
2029 | $45.0b | 18.27% |
2030 | $54.2b | 20.54% |
2031 | $59.2b | 9.21% |
2032 | $62.8b | 6.00% |
2024 | 9.09% | 7.02% |
---|---|---|
2025 | 6.04% | 33.55% |
2026 | 6.25% | 3.48% |
2027 | 6.61% | 5.76% |
2028 | 7.42% | 12.25% |
2029 | 8.17% | 10.11% |
2030 | 9.10% | 11.38% |
2031 | 9.41% | 3.41% |
2032 | 9.45% | 0.43% |
30 UnitedHealth Analysts have issued a net profit forecast 2025. The average UnitedHealth net profit estimate is $14.9b . This is 30.21% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $16.0b 24.77% , the lowest is $14.2b 33.21% .
This results in the following potential growth metrics and future Net Margins:
2024 | $14.4b | 35.64% |
---|---|---|
2025 | $14.9b | 3.17% |
2026 | $16.2b | 8.90% |
2027 | $19.0b | 17.11% |
2028 | $24.5b | 29.49% |
2029 | $29.5b | 20.28% |
2030 | $39.3b | 33.02% |
2031 | $45.5b | 15.98% |
2032 | $50.9b | 11.75% |
2024 | 3.60% | 40.25% |
---|---|---|
2025 | 3.28% | 8.86% |
2026 | 3.44% | 4.88% |
2027 | 3.83% | 11.34% |
2028 | 4.79% | 25.07% |
2029 | 5.36% | 11.90% |
2030 | 6.59% | 22.95% |
2031 | 7.24% | 9.86% |
2032 | 7.66% | 5.80% |
30 Analysts have issued a UnitedHealth forecast for earnings per share. The average UnitedHealth EPS is $16.38 . This is 30.00% lower than earnings per share in the financial year 2024. The highest EPS forecast is $17.66 24.53% , the lowest is $15.68 32.99% .
This results in the following potential growth metrics and future valuations:
2024 | $15.51 | 35.00% |
---|---|---|
2025 | $16.38 | 5.61% |
2026 | $17.84 | 8.91% |
2027 | $20.89 | 17.10% |
2028 | $27.06 | 29.54% |
2029 | $32.54 | 20.25% |
2030 | $43.29 | 33.04% |
2031 | $50.21 | 15.99% |
2032 | $56.11 | 11.75% |
Current | 14.88 | 61.14% |
---|---|---|
2025 | 21.26 | 42.83% |
2026 | 19.52 | 8.18% |
2027 | 16.67 | 14.60% |
2028 | 12.87 | 22.80% |
2029 | 10.70 | 16.86% |
2030 | 8.05 | 24.77% |
2031 | 6.94 | 13.79% |
2032 | 6.21 | 10.52% |
Based on analysts' sales estimates for 2025, the UnitedHealth stock is valued at an EV/Sales of 0.80 and an P/S ratio of 0.70 .
This results in the following potential growth metrics and future valuations:
Current | 0.86 | 45.91% |
---|---|---|
2025 | 0.80 | 6.80% |
2026 | 0.77 | 3.82% |
2027 | 0.73 | 4.89% |
2028 | 0.71 | 3.49% |
2029 | 0.66 | 6.98% |
2030 | 0.61 | 7.60% |
2031 | 0.58 | 5.28% |
2032 | 0.55 | 5.24% |
Current | 0.75 | 46.48% |
---|---|---|
2025 | 0.70 | 6.55% |
2026 | 0.67 | 3.82% |
2027 | 0.64 | 4.89% |
2028 | 0.62 | 3.48% |
2029 | 0.57 | 6.99% |
2030 | 0.53 | 7.60% |
2031 | 0.50 | 5.27% |
2032 | 0.47 | 5.25% |
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Sep 12 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Sep 09 2025 |
Bernstein |
Outperform
➜
Outperform
|
Unchanged | Sep 05 2025 |
Barclays |
Overweight
➜
Overweight
|
Unchanged | Sep 04 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Aug 26 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Aug 20 2025 |
B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Aug 18 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Sep 12 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Sep 09 2025 |
Unchanged
Bernstein:
Outperform
➜
Outperform
|
Sep 05 2025 |
Unchanged
Barclays:
Overweight
➜
Overweight
|
Sep 04 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Aug 26 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Aug 20 2025 |
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Aug 18 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.